Kringle Pharma, Inc.
Announcement of Initiation of Joint Research with Keio University on Acute Phase Protein Biomarkers for Predicting Natural Recovery and Assessing Treatment Efficacy in Spinal Cord Injury
Entered into a joint research agreement with Keio University on acute-phase protein biomarkers for spinal cord injury prognosis and treatment effect evaluation. Continued preparations for a Phase III add-on clinical trial of the HGF formulation KP-100IT and advancing North American expansion. While the direct impact on performance is expected to be minor, research results are anticipated to contribute to the sophistication of clinical trial analysis and optimization of treatment strategies.
Key Figures
- Conclusion of joint research agreement (with Keio University)
- Preparation for Phase III add-on clinical trial domestically
- Preparation for North American expansion
AI要約
Key points of the news
Kringle Pharma has entered into a joint research agreement with Keio University School of Medicine to advance the analysis and evaluation of acute-phase protein biomarkers used to predict natural recovery after spinal cord injury and to assess treatment effects. We will continue domestic development and North American expansion of the HGF protein drug and prepare for the Phase III add-on clinical trial. The direct impact on performance is expected to be minimal.
Outlook and impact on investors
Through the joint research, the precision of clinical trial data analysis is expected to improve and spinal cord injury acute phase treatment strategies may be optimized. In the long term, it is anticipated that there will be knowledge gains that contribute to expanding the clinical application of HGF formulations and to the approvals processes domestically and internationally. However, as of now, the direct contribution to financials is limited, so short-term reinvestment effects are unclear.
Kringle Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
